Receptor-targeted nanocarriers for therapeutic delivery to cancer

Molecular Membrane Biology

Volumn 27, Issue 7, 2010, Pages 286-298

  Yu, Bo ^a,b   Tai, Heng Chiat ^c   Xue, Weiming ^a,d   Lee, L James ^a,b   Lee, Robert J ^b,c  

^a Department of Chemical and Biomolecular Engineering ^*  (United States)

^b NSF Nanoscale Science and Engineering Center (NSEC)   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NORTHWEST UNIVERSITY   (China)

Author keywords

Drug delivery; drug targeting; nanocarriers

Indexed keywords

ALEMTUZUMAB; APTAMER; ASIALOGLYCOPROTEIN RECEPTOR; ASPARAGINASE MACROGOL; CD19 ANTIBODY; DAUNORUBICIN; DENDRIMER; DEQUALINIUM; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR; FOLIC ACID; GALACTOSE; GEMTUZUMAB OZOGAMICIN; GONADORELIN; GONADORELIN RECEPTOR; IBRITUMOMAB TIUXETAN; LIPOSOME; NANOCARRIER; PEGINTERFERON ALPHA2B; RITUXIMAB; SGT 53; TOSITUMOMAB I 131; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR; ZINOSTATIN;

BIOAVAILABILITY; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG TARGETING; MICELLE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; MICELLES; NANOCONJUGATES; NANOMEDICINE; NEOPLASMS; POLYMERS;

EID: 78049349257     PISSN: 09687688     EISSN: 14645203     Source Type: Journal    
DOI: 10.3109/09687688.2010.521200     Document Type: Review

References (141)

1. Abu Lila AS, Ishida T, Kiwada H. 2009. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv 6:1297-1309.
2. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. 2008. Factors affecting the clearance and biodistribution of polymeric nano-particles. Mol Pharm 5:505-515.
3. Aliabadi HM, Lavasanifar A. 2006. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 3:139-162.
4. Allen TM. 2002. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750-763.
5. Allen TM, Cullis PR. 2004. Drug delivery systems: Entering the mainstream. Science 303:1818-1822.
6. Arap W, Pasqualini R, Ruoslahti E. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380.
7. Balestrieri ML, Napoli C. 2007. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer 43:1242-1250.
8. Beuttler J, Rothdiener M, Muller D, Frejd FY, Kontermann RE. 2009. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug Chem 20: 1201-1208.
9. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, Rusling JF. 2009. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3:307-316.
10. Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V. 2008. Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559-2563.
11. Bonacucina G, Cespi M, Misici-Falzi M, Palmieri GF. 2009. Colloidal soft matter as drug delivery system. J Pharm Sci 98:1-42.
12. Brooks H, Lebleu B, Vives E. 2005. Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Deliv Rev 57:559-577.
13. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribu-tion properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277.
14. Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129.
15. Chang DK, Lin CT, Wu, CH, Wu HC. 2009. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4:e4171.
16. Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G. 2007. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J Am Chem Soc 129:5798-5799.
17. Clynes R, Towers T, Presta L, Ravetch J. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446.
18. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. 2004. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853-2857.
19. D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. 2003. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 92:189-197.
20. Daniels TR, Delgado T, Helguera G, Penichet ML. 2006. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121:159-176.
21. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M. 2004. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085-2091.
22. Davis ME, Chen ZG, Shin DM. 2008. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 7:771-782.
23. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G. 2002. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8:1710-1719.
24. Desgrosellier JS, Cheresh DA. 2010. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
25. Di Nenedetto M, Starzec A, Vassy R, Perret GY, Crepin M. 2008. Distinct heparin binding sites on VEGF165 and its receptors revealed by their interaction with a non sulfated glycoaminogly-can (NaPaC). Biochim Biophys Acta 1780:723-732.
26. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. 2010. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694-3706.
27. Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. 2009. Economic analysis of albumin-bound paclitaxel for the treatment of met-astatic breast cancer. J Oncol Pharm Pract 15:67-78.
28. Duncan R. 2003. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347-360.
29. Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688-701.
30. Duncan R. 2009. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt. Adv Drug Deliv Rev 61(13):1131-1148.
31. Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Advanced Drug Delivery Reviews 57:2215-2237.
32. El Bayoumi TA, Torchilin VP. 2009. Tumor-targeted nanomedi-cines: Enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973-1980.
33. Fang X, Tan W. 2010. Aptamers generated from cell-SELEX for molecular medicine: A chemical biology approach. Acc Chem Res 43:48-57.
34. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315-6320.
35. Farokhzad OC, Langer R. 2009. Impact of nanotechnology ondrug delivery. Acs Nano 3:16-20.
36. Futaki S, Masui Y, Nakase I, Sugiura Y, Nakamura T, Kogure K, Harashima H. 2005. Unique features of a pH-sensitive fuso-genic peptide that improves the transfection efficiency of cat-ionic liposomes. J Gene Med 7:1450-1458.
37. Ganta S, Devalapally H, Shahiwala A, Amiji M. 2008. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 126:187-204.
38. Garanger E, Boturyn D, Coll JL, Favrot MC, Dumy P. 2006. Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands. Org Biomol Chem 4:1958-1965.
39. Gindy ME, Prud'homme RK. 2009. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 6:865-878.
40. Gosk S, Vermehren C, Storm G, Moos T. 2004. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ per-fusion. J Cereb Blood Flow Metab 24:1193-1204.
41. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
42. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC. 2007. Targeted nanopar-ticles for cancer therapy. Nano Today 2:14-21.
43. Gullotti E, Yeo Y. 2009. Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery. Mol Pharm 6:1041-1051.
44. Hawkins MJ, Soon-Shiong P, Desai N. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876-885.
45. Heath JR, Davis ME. 2008. Nanotechnology and cancer. Annu Rev Med 59:251-265.
46. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612.
47. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W. 2009. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10:862-868.
48. Jagur-Grodzinski J. 2009. Polymers for targeted and/or sustained drug delivery. Polymers for Adv Technol 20:595-606.
49. Jain RK. 1999. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1:241-263.
50. Kakudo T, Chaki S, Futaki S, Nakase I, Akaji K, Kawakami T, Maruyama K, Kamiya H, Harashima H. 2004. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: An artificial viral-like delivery system. Biochemistry 43:5618-5628.
51. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. 1997. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75.
52. Kluza E, Van Der Schaft DW, Hautvast PA, Mulder WJ, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K. 2010. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultiva-lent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 10:52-58.
53. Krishna AD, Mandraju RK, Kishore G, Kondapi AK. 2009. An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One 4:e7240.
54. Laginha K, Mumbengegwi D, Allen T. 2005. Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotox-icity. Biochim Biophys Acta 1711:25-32.
55. Laginha KM, Moase EH, Yu N, Huang A, Alien TM. 2008. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer. J Drug Target 16: 605-610.
56. Lam R, Ho D. 2009. Nanodiamonds as vehicles for systemic and localized drug delivery. Expert Opin Drug Deliv 6: 883-895.
57. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. 2008. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cyto-toxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112:5180-5189.
58. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. 2006. LHRH-conjugated magnetic iron oxide nano-particles for detection of breast cancer metastases. Breast Cancer Res Treat 99:163-176.
59. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. 2008. Nanotechnology and aptamers: Applications in drug delivery. Trends Biotechnol 26:442-449.
60. Li SD, Huang L. 2008. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496-504.
61. Loomis K, Smith B, Feng Y, Garg H, Yavlovich A, Campbell-Massa R, Dimitrov DS, Blumenthal R, Xiao X, Puri A. 2010. Specific targeting to B cells by lipid-based nano-particles conjugated with a novel CD22-ScFv. Exp Mol Pathol 88:238-249.
62. Lopes De Menezes DE, Pilarski LM, Allen TM. 1998. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320-3330.
63. Low PS, Henne WA, Doorneweerd DD. 2008. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120-129.
64. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K, Brahmbhatt VN, Phillips L, Pattison ST, Petti C, Stillman B, Graham RM, Brahmbhatt H. 2009. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 27:643-651.
65. MacDiarmid JA, Madrid-Weiss J, Amaro-Mugridge NB, Phillips L, Brahmbhatt H. 2007a. Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors. Cell Cycle 6:2099-2105.
66. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, Haasdyk JE, Dickson KA, Brahmbhatt VN, Pattison ST, James AC, Al Bakri G, Straw RC, Stillman B, Graham RM, Brahmbhatt H.2007b. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of che-motherapeutics. Cancer Cell 11:431-445.
67. Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y, Nakanishi H. 2010. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macro-phages from patients with gastric cancer. Cancer Sci 101: 1670-1677.
68. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumori-tropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392.
69. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M, Watanabe N. 2004. Phase I clinical trial and pharmacokinetic evaluations of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775-1781.
70. McCarthy JR, Weissleder R. 2008. Multifunctional magnetic nano-particles for targeted imaging and therapy. Adv Drug Deliv Rev 60:1241-1251.
71. Miele E, Spinelli GP, Tomao F, Tomao S. 2009. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99-105.
72. Mishra B, Patel BB, Tiwari S. 2010. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 6:9-24.
73. Misra R, Sahoo SK. 2010. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 39:152-163.
74. Mukhopadhyay A, Weiner H. 2007. Delivery of drugs and macro-molecules to mitochondria. Adv Drug Deliv Rev 59:729-738.
75. Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, Oku N. 2010. A novel DDS strategy, 'dual-targeting', and its application for antineovascular therapy. Cancer Lett 287:165-171.
76. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. 2009. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharmaceut Sci 38:185-196.
77. Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR. 2010. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 143:265-273.
78. Neidle S, Thurston DE. 2005. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5:285-296.
79. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123-132.
80. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. 2007. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86-94.
81. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. 2004. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8:335-353.
82. Nobs L, Buchegger F, Gurny R, Allemann E. 2004. Current methods for attaching targeting ligands to liposomes and nano-particles. J Pharm Sci 93:1980-1992.
83. Norberto SE, Kakar SS. 2009. The use of nanoparticles in LHRH receptor targeted therapy for cancer. Exp Mol Pathol.
84. Ong W, Yang Y, Cruciano AC, McCarley RL. 2008. Redox-trig-gered contents release from liposomes. J Am Chem Soc 130:14739-14744.
85. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. 2002. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181.
86. Park KM, Suh K, Jung H, Lee DW, Ahn Y, Kim J, Baek K, Kim K. 2009. Cucurbituril-based nanoparticles: A new efficient vehicle for targeted intracellular delivery of hydrophobic drugs. Chem Commun (Camb):71-73.
87. Paschke M. 2006. Phage display systems and their applications. Appl Microbiol Biotechnol 70:2-11.
88. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M. 2003. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63:7400-7409.
89. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. 2010. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31:358-365.
90. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. 2007. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751-760.
91. Peer D, Margalit R. 2004a. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108:780-789.
92. Peer D, Margalit R. 2004b. Tumor-targeted hyaluronan nanolipo-somes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neo-plasia 6:343-353.
93. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W. 2008. Applications of aptamers in cancer cell biology. Anal Chim Acta 621:101-108.
94. Piddock LJV. 2006. Multidrug-resistance efflux pumps-not just for resistance. Nature Rev Microbiol 4:629-636.
95. Qian ZM, Li H, Sun H, Ho K. 2002. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561-587.
96. Rajendran L, Knolker HJ, Simons K. 2010. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 9:29-42.
97. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. 2009. Nanomedicine-challenge and perspectives. Angewandte Chemie-Int Ed 48:872-897.
98. Ruoslahti E. 2002. Specialization of tumour vasculature. Nat Rev Cancer 2:83-90.
99. Ruoslahti E, Bhatia SN, Sailor MJ. 2010. Targeting of drugs and nanoparticles to tumors. J Cell Biol 22(188):759-768.
100. Sapra P, Allen TM. 2003. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42:439-462.
101. Saul JM, Annapragada AV, Bellamkonda RV. 2006. A dual-ligand approach for enhancing targeting selectivity of therapeutic nano-carriers. J Control Release 114:277-287.
102. Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW. 2008. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. J Drug Targeting 16:601-604.
103. Sawyers C. 2004. Targeted cancer therapy. Nature 432:294-297.
104. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ. 2002. Hepatic drug targeting: Phase I. Evaluation of polymer bound doxorubicin. J Clin Oncol 20:1668-1676.
105. Sharkey RM, Goldenberg DM. 2006. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226-243.
106. Sharkey RM, Goldenberg DM. 2008. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 60:1407-1420.
107. Shi M, Ho K, Keating A, Shoichet MS. 2009a. Doxorubicin-conjugated lmmuno-nanoparticles for intracellular anticancer drug delivery. Adv Functio Mater 19:1689-1696.
108. Shi M, Lu J, Shoichet MS. 2009b. Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer. J Mater Chem 19:5485-5498.
109. Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H, Whitehorn E, Moore KW, Swimmer C, Perlroth V, Vogt M, Kolkman J, Stemmer WP. 2005. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556-1561.
110. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. 1998. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4:623-626.
111. Soussan E, Cassel S, Blanzat M, Rico-Lattes I. 2009. Drug delivery by soft matter: Matrix and vesicular carriers. Angew Chem Int Ed Engl 48:274-288.
112. Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D, Ruoslahti E. 2010. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031-1035.
113. Sundaram S, Durairaj C, Kadam R, Kompella UB. 2009. Luteiniz-ing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 8:1655-1665.
114. Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA. 2009. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc 131:1384-1385.
115. Tkachenko AG, Xie H, Coleman D, Glomm W, Ryan J, Anderson MF, Franzen S, Feldheim DL. 2003. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc 125:4700-4701.
116. Toma A, Otsuji E, Kuriu Y, Okamoto K, Ichikawa D, Hagiwara A, Ito H, Nishimura T, Yamagishi H. 2005. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer 93:131-136.
117. Torchilin VP. 2009. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71: 431-444.
118. Torchilin VP. 2005a. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2:319-327.
119. Torchilin VP. 2005b. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
120. Torchilin VP. 2006a. Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532-1555.
121. Torchilin VP. 2006b. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8:343-375.
122. Torchilin VP. 2007. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Aaps J 9:E128-147.
123. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. 2003. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc Nat Acad Sci USA 100:6039-6044.
124. Veiseh O, Gunn JW, Zhang M. 2010. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 62:284-304.
125. Vives E, Schmidt J, Pelegrin A. 2008. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786:126-138.
126. Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. 2005. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery. Pharm Res 22: 1906-1917.
127. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J Jr, Schwartz D, Kreuter J, von Briesen H, Langer K. 2010. Enhanced drug targeting by attachment of an anti alphav integ-rin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31:2388-2398.
128. Wagner V, Dullaart A, Bock AK, Zweck A. 2006. The emerging nanomedicine landscape. Nat Biotechnol 24:1211-1217.
129. Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. 1998. DQAsomes: A novel potential drug and gene delivery system made from Dequalinium. Pharm Res 15:334-337.
130. Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Stahl S. 2004. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 17:455-462.
131. Wu J, Nantz MH, Zern MA. 2002. Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front Biosci 7:d717-725.
132. Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H. 2008. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 1778:423-432.
133. Yamada Y, Harashima H. 2008. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 60:1439-1462.
134. Yan AC, Levy M. 2009. Aptamers and aptamer targeted delivery. RNA Biol 6:316-320.
135. Yang J, Lee CH, Ko HJ, Suh JS, Yoon HG, Lee K, Huh YM, Haam S. 2007. Multifunctional magneto-polymeric nanohy-brids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl 46:8836-8839.
136. Yousif LF, Stewart KM, Kelley SO. 2009. Targeting mitochondria with organelle-specific compounds: Strategies and applications. Chembiochem 10:1939-1950.
137. Yu B, Zhao X, Lee LJ, Lee RJ. 2009. Targeted delivery systems for oligonucleotide therapeutics. Aaps J 11:195-203.
138. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.
139. Zhang Z, Cao W, Jin H, Lovell JF, Yang M, Ding L, Chen J, Corbin I, Luo Q, Zheng G. 2009. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem Int Ed Engl 48:9171-9175.
140. Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G. 2010. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6:430-437.
141. Zhao X, Li H, Lee RJ. 2008. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 5:309-319.